Liothyronine Sodium Tablets Recalled for Failed Impurity and Degradation Specifications
Sun Pharmaceutical is recalling 7,392 bottles of Liothyronine Sodium Tablets (Lot DND0058A) nationwide due to failed impurity and degradation specifications. Patients should contact their healthcare provider.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. Impurities or degradation in a prescription thyroid medication represents a risk-of-harm scenario, meeting the criterion for High severity despite the absence of documented harm.
Plain-English summary
Sun Pharmaceutical Industries Inc is recalling 7,392 bottles of Liothyronine Sodium Tablets, USP, 5 mcg (NDC 62756-589-88, Lot DND0058A, expiration 12/2023) due to failed impurity and degradation specifications. The tablets were manufactured by Sun Pharmaceutical Industries Ltd in India and distributed nationwide in the United States.
The recall affects patients who have been prescribed tablets from the affected lot. Liothyronine Sodium is a prescription thyroid hormone medication.
Patients currently taking tablets from the recalled lot should contact their healthcare provider for guidance. Consumers with unused tablets from this lot should not use them and should consult their healthcare provider or pharmacist about proper disposal.
The recalled product
- Product
- LIOTHYRONINE SODIUM (LIOTHYRONINE SODIUM)
- Brand
- LIOTHYRONINE SODIUM
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Category
- Drug — Thyroid Hormone
- Hazard
- Affected units
- 7,392
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: DND0058A
- Exp. Date 12/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by SUN PHARMACEUTICAL INDUSTRIES INC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · LIOTHYRONINE SODIUM
- ModerateLiothyronine Sodium tablets recalled due to failed impurity and degradation specifications
FDA (Drugs) · 2023-12-20
- HighLiothyronine Sodium Tablets Recalled for Failed Impurity Specifications
FDA (Drugs) · 2023-11-08
- ModerateSigmaPharm Recalls Liothyronine Sodium Tablets Due to Cross-Contamination
FDA (Drugs) · 2014-05-28
Same manufacturer · SUN PHARMACEUTICAL INDUSTRIES INC
See all →- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08
- HighPerampanel Prescription Tablets Recalled for Labeling Mix-up
FDA (Drugs) · 2026-07-01
- HighBudesonide inhalation ampules contain black and brown specks and particles
FDA (Drugs) · 2026-06-17
- SevereDoxorubicin liposome injection vials contain glass particulate matter
FDA (Drugs) · 2026-06-17
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17